Last month at the "den" there was a major concern about
Last month at the "den" there was a major concern about board members receiving 100k in shares. This particular poster stated that if this trend continues thats 9m shares at 0.0 and a 2150% increase in shares given to the Board of Directors. Well I saw no commentary last night regarding this statement as the "poster" had the ability to actually admit we were not going to see 9m shares at 0.0. and a 2150% increase in shares. YESTERDAY AFTERNOON THE BOD'S WERE GIVEN 4K SHARES FOR ATTENDING THEIR MEETING. THE SENSATIONALISM USED TO TALK IN THE STOCK DIDN'T WORK AGAIN AS CLEARLY THIS POSTER IS NOT LONG OR IF HIS IS VERY NOMINAL.
Look at the trend from this poster. Mid December he pulled out the "boogeyman" attempt from 12/15 to 12/19. Why because during 2014 on 4 to 5 seperate occasions scrc could not break .14. LOOK AT THE TIMING OF THE BOOGEYMAN SCRC WAS SITTING AT .14. IS THAT A COINCIDENCE THAT FOR THE 1ST TIME IN 2 YEARS THIS "POSTER" PULLS OUT THE "BOOGEYMAN" EXACTLY AT .14 WHERE IT WAS A VERY ROUGH SPOT FOR SCRC TO GET THRU.
My Observation most longs would feel pretty good about scrc being .20 to .21 this particular "poster" does he seem europhric to you????? I mean after all dec 12th we sat at .1097 and now we sit at .20 6 to 7 weeks later and does he seem happy or happier than most????????? All I hear is things like if scrc does x amount in january it will kill the sp. If scrc matches q4 of 2014 with a same # in q1 2015 it will kill the sp.
Regarding the "poster's" price to sell since when did he know everyone's parameter to sell?????? How does he know people's price to sell is 40% higher????? Actually isn't this the same "poster" who said be nimble and vigilant??????? is a 40% price to sell considered nimble and vigilant??????? What this poster does he in effect puts on a straddle so he can hedge all the plethoria of rhetoric that comes out of his mouth.
Bottom Line: As Guts stated the higher SCRC goes he will be gone and massive crew that he has working our running out of stories. The fundamentals are what counts here. We can now put to rest the 9m shares theory as well as the 2150% surge in shares to bod.
ScripsAmerica Inc (SCRC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
Top 5 Most Recently Viewed Articles
Heritage Commerce Corp Expands Board with New Addition Heritage Commerce Corp (NASDAQ: HTBK), the parent company of Heritage Bank of Commerce, recently celebrated the expansion of its Board of Directors with the appointment of Christopher J. Abate. This marks an important milestone as the Board now comprises nine directors, increasing from the previous eight. Welcoming a...
Continue Reading
North American Construction Group Ltd. Reports Year-End Results North American Construction Group Ltd. (TSX:NOA/NYSE:NOA) has reported its financial results for the fourth quarter and the whole year of 2024. The company continues to showcase significant revenues while navigating challenges in equipment utilization and market demands. Overall, the figures presented in...
Continue Reading
Cycurion's New Contract Highlights Commitment to Modernization Cybersecurity and IT services company Cycurion, Inc. (NASDAQ: CYCU) recently announced a significant achievement with its latest contract. The company has partnered with a leading telecommunications provider for a vital initiative aimed at modernizing emergency warning networks for one of the federal...
Continue Reading
Maxeon Solar Technologies' Revenue Decline The financial results for the first half of 2025 revealed a revenue of $39 million for Maxeon Solar Technologies. Strategic Shift Amid Industry Challenges Facing continued pressure from market conditions, Maxeon is undergoing significant business transformation aimed at enhancing fiscal discipline. CEO Commentary on CBP...
Continue Reading
Reading International Reports Record-Breaking Holiday Ticket Sales Reading International, Inc. (NASDAQ: RDI), a prominent player in the cinema and real estate industries, has made a remarkable announcement regarding its holiday box office results for 2024. With entertainment fast becoming an essential part of our culture, Reading has successfully leveraged the release of...
Continue Reading